Maryland Has 2nd Highest Percentage of Life Scientists vs. All Other Occupations

Published on :

Life Scientists as a Percentage of All Occupations
This indicator represents the percentage of life scientists in a state’s workforce. Life scientists are identified from standard occupational codes that include agricultural and food scientists, biological scientists, conservation scientists and foresters, medical scientists, and postsecondary teachers in these fields. A high share of life scientists in a state’s workforce could indicate a robust cluster of life sciences industries such as pharmaceutical and medicine manufacturing. States in the top quartile for this indicator also tend to contain agriculture-intensive industries.

Pacific Biosciences Acquires Baltimore’s Circulomics – A Leading High Molecular Weight DNA Extraction Company

Published on :

Pacific Biosciences of California, Inc. (Nasdaq: PACB) (“Pacific Biosciences” or “PacBio”), a leading provider of high-quality, long-read sequencing platforms, announced today that it acquired Circulomics Inc. (“Circulomics”), a Maryland-based biotechnology company focused on delivering highly differentiated sample prep products that enable genomic workflows. Scientists recognize Circulomics as a leader in extracting high quality, high molecular weight (HMW) DNA from almost any sample type. These products are commonly used for long read applications across a diverse set of markets including, human biomedical research, plant and animal sciences and microbiology.

Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial

Published on :

Novavax, Inc. (Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall, and met the primary endpoint in its PREVENT-19 pivotal Phase 3 trial. The study enrolled 29,960 participants across 119 sites in the U.S. and Mexico to evaluate efficacy, safety and immunogenicity, with an emphasis on recruiting a representative population of communities and demographic groups most impacted by the disease.

Gain Therapeutics Announces Issuance of Two New PCT Patents Covering GBA and GALC Modulator Compounds for Treatment of CNS Disorders

Published on :

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, today announced the publication of two PCT patents. PCT/IB2020/061158 and PCT/IB2020/0611156 are directed at compounds targeting misfolded beta-​glucocerebrosidase (GBA) and galactosylceramidase (GALC) respectively, addressing central nervous system (CNS) and demyelinating disorders such as Parkinson’s Disease, Lewy body dementia and Alzheimer’s.

Adaptive Phage Therapeutics Announces Collaboration with Oyster Point Pharma to Target Ophthalmic Diseases

Published on :

Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced a newly-formed research collaboration with Oyster Point Pharma, Inc. (Nasdaq: OYST) for developing therapies, using APT’s PhageBank™ technology, potentially targeting multiple ophthalmic diseases.

BBJ: Curio Wellness plots major expansion with $22M in new funding

Published on :

Curio Wellness is planning significant expansions of its Lutherville-Timonium medical cannabis growing and processing operations, armed with $22 million in newly raised equity funding and a $26 million mortgage deal.

Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus, Virus-Like Particle Vaccine Candidate

Published on :

Emergent BioSolutions Inc. (NYSE:EBS) announced two-year persistence data from its Phase 2 clinical study evaluating the safety and immunogenicity of the company’s investigational chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate in 415 healthy adults.

Celularity and Gaithersburg’s MaxCyte Sign Strategic Platform License to Advance Celularity’s Off-the-shelf Allogeneic Cellular Therapy Product Candidates

Published on :

Celularity, Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, and MaxCyte, Inc., a leading provider of cell-engineering platform technologies for next generation cell-based therapies, today announce the signing of a strategic platform license.